Raymond James raises Edgewise Therapeutics price target on FDA feedback

Raymond James raised its price target on Edgewise Therapeutics (EWTX) to $85 from $66, maintaining a Strong Buy rating. This follows FDA feedback on EDG-7500 for hypertrophic cardiomyopathy. EWTX stock is up 116% over the past year and 51% year-to-date, trading at $38.90. The company recently sold its muscular dystrophy business for $1.55 billion, focusing on cardiovascular disease. Analysts William Blair and H.C. Wainwright also issued positive ratings and targets.

Original reporting
Published Nov 5, 2026, 3:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$EWTX
Bullish
high confidence
Mentioned
$EWTX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$EWTXBullishMed
01

Why it matters

Analyst upgrades could attract new capital and improve liquidity.

02

Market read

New analyst target may drive short‑term buying interest in EWTX.

03

What to watch

Potential regulatory delays or trial enrollment challenges could temper upside.

Relevance 7/10Novelty 6/10Timing: today

Background

Edgewise Therapeutics is advancing its cardiac pipeline after selling its muscular‑dystrophy business.

Company-level read

Ticker impact

$EWTXBullishHigh confidence
Context

Raymond James raised its price target for Edgewise Therapeutics to $85 from $66 after FDA phase‑2 feedback on EDG‑7500.

Expected impact

likely upward pressure as investors price in the higher target.

Evidence & confidence

The new target reflects confidence in the upcoming phase‑3 trial and potential market advantage.

Market effects

Positive outlook may lift other small‑cap biotech stocks focused on cardiac therapies.

U.S. biotech sector could see modest gains.

Limited to investors tracking FDA‑related biotech developments.

Counterpoint

The price target increase may be premature without phase‑3 data; risk of overvaluation.

Key entities

  • Raymond James

    Raised price target and maintained Strong Buy rating.

  • Edgewise Therapeutics

    Biotech firm developing EDG‑7500 for hypertrophic cardiomyopathy.

Related articles

$EWTXMed

Edgewise submits phase 3 protocol for heart drug EDG-7500

Edgewise Therapeutics (EWTX) submitted a Phase 3 protocol for EDG-7500, a drug for hypertrophic cardiomyopathy, to the FDA. The STRATUS-HCM trial will include 600 adults, with primary endpoint being change in peak oxygen consumption after 24 weeks. The company plans to start the trial in Q4 2026, with consistent feedback from global regulators.

$EWTXMedAI 8/10

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

Edgewise Therapeutics (EWTX) received positive FDA feedback on its EDG-7500 drug for hypertrophic cardiomyopathy (HCM). The Phase 3 trial, STRATUS-HCM, will start in Q4 2026, featuring a tolerability-based dose escalation plan without echo monitoring. The trial aims to enroll 600 adults with symptomatic HCM, with peak VO₂ as the primary endpoint.

$EWTXHigh

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

Edgewise Therapeutics, Inc. (EWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Edgewise Therapeutics Reports Third Quarter 2026 Financial Results – Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – – Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardio